Precision medicine for metastatic breast cancer—limitations and solutions

被引：0

作者：

Monica Arnedos

Cecile Vicier

Sherene Loi

Celine Lefebvre

Stefan Michiels

Herve Bonnefoi

Fabrice Andre

机构：

[1] Gustave Roussy and Université Paris Sud,Department of Medical Oncology

[2] INSERM Unit U981,Department of Biostatistics and Epidemiology

[3] Gustave Roussy and Université Paris Sud,Division of Research and Cancer Medicine

[4] Gustave Roussy and Université Paris Sud,Department of Medical Oncology and INSERM U916

[5] Peter MacCallum Cancer Centre,undefined

[6] University of Melbourne,undefined

[7] Institut Bergonié,undefined

来源：

Nature Reviews Clinical Oncology | 2015年 / 12卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Recent research data defining the genomic landscape of breast cancer have reinforced the notion that this disease is driven by genomic alterationsSo far very few gene drivers validated in breast cancer have been identified, including ESR1, ERBB 2, PIK3CA and ATK1Identification of drivers, characterization of resistant clones, identification of DNA repair defects and mechanisms of immune suppression are potential uses of genomics to personalize medicineThe development of precision medicine for the treatment of breast cancer has several major challenges that include low frequency of targetable molecular alterations, feasibility of high-throughput technologies and availability of targeted therapy

引用

页码：693 / 704

页数：11

共 50 条

[1] Precision medicine for metastatic breast cancer-limitations and solutions
Arnedos, Monica
Vicier, Cecile
Loi, Sherene
Lefebvre, Celine
Michiels, Stefan
Bonnefoi, Herve
Andre, Fabrice
NATURE REVIEWS CLINICAL ONCOLOGY, 2015, 12 (12) : 693 - 704
[2] Current limitations of precision medicine in the breast cancer field
Andre, F.
EUROPEAN JOURNAL OF CANCER, 2014, 50 : S104 - S105
[3] Precision medicine improves outcomes in metastatic breast cancer
Gennari, Alessandra
NATURE, 2022,
[4] From precision medicine to personalized medicine in metastatic breast cancer patients
Andre, Fabrice
MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
[5] Precision medicine for HER2 negative metastatic breast cancer
Hara, Fumikata
ANNALS OF ONCOLOGY, 2016, 27
[6] Precision medicine in breast cancer
Naito, Yoichi
Urasaki, Tetsuya
CHINESE CLINICAL ONCOLOGY, 2018, 7 (03)
[7] Accelerating precision medicine in metastatic prostate cancer
Joaquin Mateo
Rana McKay
Wassim Abida
Rahul Aggarwal
Joshi Alumkal
Ajjai Alva
Felix Feng
Xin Gao
Julie Graff
Maha Hussain
Fatima Karzai
Bruce Montgomery
William Oh
Vaibhav Patel
Dana Rathkopf
Matthew Rettig
Nikolaus Schultz
Matthew Smith
David Solit
Cora Sternberg
Eliezer Van Allen
David VanderWeele
Jake Vinson
Howard R. Soule
Arul Chinnaiyan
Eric Small
Jonathan W. Simons
William Dahut
Andrea K. Miyahira
Himisha Beltran
Nature Cancer, 2020, 1 : 1041 - 1053
[8] Accelerating precision medicine in metastatic prostate cancer
Mateo, Joaquin
McKay, Rana
Abida, Wassim
Aggarwal, Rahul
Alumkal, Joshi
Alva, Ajjai
Feng, Felix
Gao, Xin
Graff, Julie
Hussain, Maha
Karzai, Fatima
Montgomery, Bruce
Oh, William
Patel, Vaibhav
Rathkopf, Dana
Rettig, Matthew
Schultz, Nikolaus
Smith, Matthew
Solit, David
Sternberg, Cora
Van Allen, Eliezer
VanderWeele, David
Vinson, Jake
Soule, Howard R.
Chinnaiyan, Arul
Small, Eric
Simons, Jonathan W.
Dahut, William
Miyahira, Andrea K.
Beltran, Himisha
NATURE CANCER, 2020, 1 (11) : 1041 - 1053
[9] Precision medicine in breast cancer (Review)
Papalexis, Petros
Georgakopoulou, Vasiliki Epameinondas
Drossos, Panagiotis V.
Thymara, Eirini
Nonni, Aphrodite
Lazaris, Andreas C.
Zografos, George C.
Spandidos, Demetrios A.
Kavantzas, Nikolaos
Thomopoulou, Georgia Eleni
MOLECULAR AND CLINICAL ONCOLOGY, 2024, 21 (05)
[10] Breast cancer in the era of precision medicine
Sarhangi, Negar
Hajjari, Shahrzad
Heydari, Seyede Fatemeh
Ganjizadeh, Maryam
Rouhollah, Fatemeh
Hasanzad, Mandana
MOLECULAR BIOLOGY REPORTS, 2022, 49 (10) : 10023 - 10037

← 1 2 3 4 5 →